GT Biopharma Inc

( )
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield

Message Boards



Health Technology » Pharmaceuticals Other

Company Profile

GT Biopharma, Inc. is engages in the development of immunotherapies for the treatment of cancer. Its product includes medicines like OXS-1550, for Acute lymphoblastic leukemia & Non-Hodgkin's lymphoma, OXS-1650 for Refractory Epithelial Ovarian cancer, OXS-3550 for B-cell malignancies, OXS-4550 for Triple Negative Breast & other TAG-72+ cancers, OXS-1750 for Multiple Myeloma & Secondary Osteolytic Lesions, OXS-1950 for FZD7+ Taxol Refractory Solid Tumors, and OXS-2050 for Triple Negative Breast & other ICAM+ cancers. The company was founded in 1965 and is headquartered in Tampa, FL.